16th Jul 2007 07:00
Tepnel Life Sciences PLC16 July 2007 Tepnel Life Sciences plc Extends Licence Agreement with Luminex Manchester, UK, 16 July 2007: Tepnel Life Sciences PLC (AIM: TED), theinternational Molecular Diagnostics and Research Products & Services group,announces it has agreed to an extension of the licence with Luminex Corporation(NASDAQ: LMNX) for access to the Luminex(R) xMAP(R) platform. The Luminex xMAPtechnology is incorporated into Tepnel's innovative molecular diagnosticsproducts. Tepnel's LifeMatch products are used for the measurement and detection of HLA(Human Leukocyte Antigen) markers which are used in both bone marrow and solidorgan transplantation. These products allow the rapid analysis of a donor's HLAtype to determine if they are a potential match for the patient waiting for abone marrow transplantation or a patient on a solid organ waiting list. Tepnel develops highly multiplexed DNA and protein based assays and userfriendly software for its highly successful LifeMatch product line. The Luminextechnology allows Tepnel Lifecodes' customers to analyze up to 100 simultaneousreactions on a single patient's sample in a user friendly, cost effective mannerwith minimal hands-on time. Tepnel's CEO Ben Matzilevich commented "We are pleased to extend our agreementfor the use of Luminex's xMAP technology for our Molecular Diagnostics Division.The xMAP technology provides a powerful platform when combined with ourstate-of-the-art LifeMatch family of Lifecodes assays and software. We continueto extend our leadership position in the field of organ transplantation andanticipate strong continued growth for the LifeMatch product lines." Luminex Corporation President and CEO Patrick Balthrop stated, "Customers in theHLA market have led the way toward improving efficiency of diagnostic testingthrough multiplexing. HLA customers have rapidly converted standardprotein-based ELISA tests to multiplexed tests based on xMAP technology.Additionally, these same customers take advantage of the flexibility of xMAPtechnology by also testing nucleic acids, where up to 100 different markers persample are analyzed routinely. We are pleased to continue working with Tepnelto deliver multiplexed solutions in the HLA market and continue to beenthusiastic about xMAP's ability to satisfy the increasing performance demandsof our partners and customers." Tepnel's LifeMatch product line is rapidly gaining market share in the USA,Europe and ROW. In January of this year, Tepnel extended the LifeMatch productlines with two new product offerings, LSA(TM) and DSA(TM). LSA is a highlymultiplexed assay system consisting of more than 150 cloned recombinantproteins. This assay allows clinicians to accurately identify permissibleallele level antigens in highly sensitized patients in order to minimize thechance of rejection and ensure a better outcome. The DSA product line allowsclinicians to screen the patient for the presence of antibodies against HLAantigens of the donor ensuring compatibility and minimizing rejection. Tepnelwill continue to expand its Lifecodes product lines in order to meet the needsof the transplant community. -Ends- For Further Information: Tepnel Life Sciences plcBen Matzilevich, CEOCarol SmithTel: 0161 946 2200 Capital MS&LMary Clark or Catie CorcoranTel: +44 20 7307 5330Email: [email protected] Notes to Editors About Tepnel Life Sciences plc Tepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services group with two divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with 195 employees. TLS provides testkits, reagents and services to two highly synergistic markets, these beingMolecular Diagnostics and Biomedical Research. The company's strategy has beento identify high growth niche opportunities within these multi-billion poundmarkets. TLS focuses on these niche opportunities with internally developedproducts, patents, expertise and know-how as well as strategic acquisitions, todevelop a leadership position within these defined market segments. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.L